Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054 13/02/2026

1,210 USD (-11,03%)

(-11,03%) 13/02/2026

Grafiek Akebia Therapeutics Inc.

Grafiek Akebia Therapeutics Inc.

1 dag1d -11,03%
1 week1w -19,33%
1 maand1m -12,32%
3 maanden3m -27,54%
6 maanden6m -63,22%
1 jaar1j -43,19%
5 jaar5j -75,15%

Akebia Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

1 december 2025 · Q32 Bio Sells Complement Inhibitor ADX-097 · Persbericht

5 september 2024 · Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis · Persbericht

3 september 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 augustus 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

2 augustus 2024 · Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights · Persbericht

1 augustus 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

29 juli 2024 · Akebia Therapeutics to Present at Upcoming Investor Conferences · Persbericht

11 juli 2024 · Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets · Persbericht

1 juli 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Profiel Akebia Therapeutics Inc.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: akebia.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe